Hostname: page-component-7b7567c8c-tnzcf Total loading time: 0 Render date: 2026-11-14T14:07:39.813Z Has data issue: false hasContentIssue false
  • English
  • Français

Grupo Espanol de Estudio Tratamiento y otras Estrategias Experimentales en Tumores Solidos (SOLTI)

Published online by Cambridge University Press:  04 December 2006

Abstract

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Grupo Espanol de Estudio Tratamiento y otras Estrategias Experimentales en Tumores Solidos (SOLTI). Clinical trials include:

  1. A phase III randomized, controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first line therapy of metastatic breast cancer.

SOLTI – Contact Details

Country

Spain

Chair

Dr H. Cortes-Funes MD, PhD

Chairman of Scientific Committee

Dr J. Baselga, MD, PhD

SOLTI – Study Details

Title

A phase III randomized, controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first line therapy of metastatic breast cancer.

Coordinator(s)

J. Baselga MD, PhD

Summary

Final Protocol Released in January 2006

  • The target accrual is 600 randomized patients, 300 in each Arm

Objective

  • The primary objectives of this trial are to demonstrate the efficacy and cardiac safety of Myocet when given in combination with trastuzumab and paclitaxel in patients with HER2 + metastatic breast cancer.

Scheme

Update

  • Clinical Trial Submission in March 2006.

Related Publications

None available

Topics

  • Anthracyclines
  • Cardiac function
  • HER2 positive patients
  • Metastatic breast cancer
  • Taxanes
  • Trastuzumab

Keywords

Myocet HER2 positive patients, metastatic breast cancer, doxorubicin, trastuzumab